Ageing, oestrogen, platelets and thrombotic risk

Virginia M. Miller, Muthuvel Jayachandran, Whyte G. Owen

Research output: Contribution to journalReview articlepeer-review

23 Scopus citations

Abstract

1. Adverse thrombotic cardiovascular events increase in women coincident with the onset of menopause. 2. Age past menopause may be an important variable in defining the benefit/risk of hormone treatments. 3. Few studies have examined hormonal status as a variable of ageing using a polygenomic approach of both humoral and cellular components of the coagulation system. 4. Longitudinal studies of a global set of platelet functions that define procoagulant activity (i.e. adhesion, aggregation, secretion and thrombin production) in individuals with documented hormonal status are needed to better understand how hormonal changes associated with ageing impact thrombotic risk.

Original languageEnglish (US)
Pages (from-to)814-821
Number of pages8
JournalClinical and Experimental Pharmacology and Physiology
Volume34
Issue number8
DOIs
StatePublished - Aug 1 2007

Keywords

  • 17β-oestradiol
  • Energy metabolism
  • Kronos Early Estrogen Prevention Study (KEEPS)
  • Mitochondria
  • Women's Health Initiative

ASJC Scopus subject areas

  • Physiology
  • Pharmacology
  • Physiology (medical)

Fingerprint Dive into the research topics of 'Ageing, oestrogen, platelets and thrombotic risk'. Together they form a unique fingerprint.

Cite this